A North Shore biotech company is partnering with a U.K. outfit to test a treatment for COVID-19.

CytoAgents Inc. partnered with Nottingham, U.K.-based Quotient Sciences to test a drug dubbed GP1681 in phase one and two Food and Drug Administration trials, which will assess safety and effectiveness of the drug.

The test drug is a small molecule inhibitor that prevents a massive cytokine release, a common reaction in people who are severely ill with COVID-19. The release, called a “cytokine storm,” damages healthy tissue.

The announcement was made Tuesday by both companies.

Advertise with us

GP1681 has been shown to safely modulate the natural immune response by tamping down various cytokines, according to the company. Preparing for the FDA trials will be done at Quotient’s Delaware County facility.

Kris B. Mamula: kmamula@post-gazette.com or 412-263-1699